Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
Myocardial infarction with non-obstructive coronary arteries" (MINOCA) occurs in 5-10% of all
patients with AMI. There are neither any randomized clinical trials in MINOCA patients
evaluating effects of secondary preventive treatments proven beneficial in patients with
classic AMI, nor any treatment guidelines.
The primary objective of this multi-national, multi-center pragmatic randomized clinical
trial is to determine whether oral beta-blockade compared to no oral beta-blockade, and
whether Angiotensin Converting Enzyme Inhibitors (ACEI/ Angiotensin Receptor Blockers (ARB)
compared to no ACEI/ARB, reduce the composite endpoint of death of any cause and readmission
because of AMI, ischemic stroke or heart failure in patients discharged with myocardial
infarction with non-obstructive coronary artery disease (MINOCA) and with no clinical signs
of heart failure and with left ventricular (LV) systolic ejection fraction ≥40%.
Phase:
Phase 4
Details
Lead Sponsor:
Uppsala University
Collaborators:
Göteborg University Karolinska Institutet New York University Oslo University Hospital University of Adelaide University of Leeds